Meloxicam

Meloxicam is associated with Lower Hospital Readmission Rates for Major Joint Replacement or Reattachment Of Lower Extremity Without Major Complication or Comorbidity (MCC) Patients at Harrisburg Hospital based on RWE Study of Medicare Claims Data

By: Sara Riascos Apr. 06, 2022

Major Joint Replacement or Reattachment Of Lower Extremity Without Major Complication or Comorbidity (MCC) is frequently associated with hospital readmission. Readmission is a hospital quality measure that reflects dimensions of quality of inpatient care and also impacts overall programs by payors such as CMS’s Star Rating Program, HRRP and Value-Based Purchasing. Meloxicam is a nonsteroidal anti-inflammatory drug. Studies show that the early use of Meloxicam attenuates postoperative pain and improves patient satisfaction when used after a TKA.

Meloxicam is associated with Lower Hospital Readmission Rates for Hip and Knee Replacement Patients at Our Lady of the Lake Regional Medical Center based on Real World Evidence Study of Medicare Claims Data

By: Sara Riascos Apr. 05, 2022

Major Joint Replacement Or Reattachment Of Lower Extremity Without Major Complication Or Comorbidity (MCC) is frequently associated with hospital readmission. Readmission is a hospital quality measure that reflects dimensions of quality of inpatient care and also impacts overall programs by payors such as CMS’s Star Rating Program, HRRP and Value-Based Purchasing. Meloxicam is a nonsteroidal anti-inflammatory drug. Studies show that the early use of Meloxicam attenuates postoperative pain and improves patient satisfaction when used after a TKA.

Meloxicam is associated with Lower Hospital Readmission Rates for Hip and Knee Replacement Patients at Virtua Voorhees Hospital based on Real World Evidence Study of Medicare Claims Data

By: Sara Riascos Apr. 01, 2022